Biogen Statistics and Revenue Totals (2023)
Last Updated on: June 8th, 2023
Here are a few of the most interesting Biogen statistics I was able to dig up including Biogen revenue totals and employee counts. As always, be sure to check back in the future as I will be updating this post as new and updated stats become available.
Biogen Facts
- Website: Official Website
- Year Founded: 1978
- Headquarters: Cambridge, MA
- Founder(s): Kenneth Murray, Phillip Sharp, Walter Gilbert, Heinz Schaller and Charles Weissmann
- Current Chief Executive: Michael Vounatsos
- Subsidiaries / Brands: Tecfidera, Avonex, Plegridy, Tysabri, Fampyra, Spinraza, Fumaderza
Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. (source)
Biogen Statistics
Biogen Revenue Totals
Biogen annual revenue:
- 2022: $10.173 billion
- 2021: $10.981 billion
- 2020: $13.444 billion
- 2019: $14.377 billion
- 2018: $13.453 billion
- 2017: $12.273 billion
- 2016: $11.448 billion
- 2015: $10.763 billion
- 2014: $9.703 billion
- 2013: $6.932 billion
Biogen annual net income:
- 2022: $3.046 billion
- 2021: $1.556 billion
- 2020: $4.000 billion
- 2019: $5.888 billion
- 2018: $4.430 billion
- 2017: $2.539 billion
- 2016: $3.702 billion
- 2015: $3.547 billion
- 2014: $2.934 billion
Please note that some of these numbers are easier to find than others. A few of these Biogen statistics come from their own reports, but some are based on news reports and not official company tallies. No information contained on DMR should be relied upon to make investment decisions. Basically, this is the best I can find and I don’t guarantee anything to be 100%.
Related Categories:
Related Tags:
